**[*HOSPITAL NAME*] Acquires New BioFire FilmArray™ Gastrointestinal Test**

**SALT LAKE CITY, Utah,** (Month XX, 2014) – [*HOSPITAL NAME*] announced today that it has acquired BioFire Diagnostics’ FilmArray Gastrointestinal (GI) Panel. The 22-target panel, which includes bacteria, viruses and parasites that cause infectious diarrhea, is the most comprehensive gastrointestinal test to be cleared by the FDA. The FilmArray GI Panel is performed directly from stool in Cary Blair transport media, takes only two minutes to set up, and produces results in about an hour.

“We have made it a top priority this year to significantly improve our lab’s testing times and accuracy, and we plan to use the FilmArray GI test to help us achieve this goal,” said [*HOSPITAL SPOKESPERSON, TITLE*]. “The faster we get test results, the faster we will be able to apply an optimized treatment plan, thus improving overall patient outcomes.”

“The excitement from the medical community about this panel has been astounding,” said Randy Rasmussen, CEO of BioFire Diagnostics. “We view this panel as a game-changer in the diagnosis of infectious diarrhea, delivering accurate and timely results. The breadth of pathogens on our GI Panel provides the big picture in gastrointestinal infectious disease, which will aid clinicians with treatment decisions for their patients.”

The FilmArray GI Panel offers clinical laboratories a user-friendly alternative to the time-consuming, labor intensive and technically complex testing methods used today while improving accuracy, timeliness and diagnostic yield.

Despite advances in food safety, sanitation and medical treatment, infectious gastroenteritis remains a significant problem in industrialized countries among all age groups. In the United States, between 200 and 375 million episodes of diarrheal illness are estimated to occur each year, resulting in 73 million physician visits, 1.8 million hospitalizations, 3,100 deaths and $6 billion in medical care and lost productivity.Early diagnosis facilitates timely and appropriate therapeutic interventions that can alleviate symptoms and prevent secondary infections.1

**About BioFire Diagnostics, LLC**

BioFire Diagnostics, LLC, a wholly owned subsidiary of bioMérieux, Inc., manufactures and distributes the user-friendly FilmArray System to hospital-based clinical laboratories across the U.S. and EU. BioFire currently offers the FDA-cleared and CE IVD marked FilmArray Respiratory Panel and FilmArray Blood Culture Identification Panel. The company continues to broaden its FilmArray test menu with regulatory applications and ongoing development of novel panels.

BioFire holds more than 85 patents related to polymerase chain reaction (PCR), and has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research and military markets. BioFire customers include the Department of Health and Human Services, the Department of Defense, state and local law enforcement and researchers and medical technicians across a spectrum of fields and industries.

For further information, please visit [www.BioFireDx.com](http://www.BioFireDx.com).

# # #

**Contact**:

BioFire Diagnostics, LLC

Mari Hoidal

801-736-6354 x774

[Mari.Hoidal@biofiredx.com](mailto:Mari.Hoidal@biofiredx.com)